http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 13 Aug 2026 16:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ensysce+Biosciences%2C++++++For%3A+Jun+30/26921902.html si-local-file:///var/storage/secattach/20260813/26921902.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ensysce+Biosciences%2C++++++For%3A+Jun+30/26921902.html Thu, 13 Aug 2026 16:32:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ensysce+Biosciences%2C++++++For%3A+Jun+30/26921902.html si-local-file:///var/storage/secattach/20260813/26921902.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Ensysce+Biosciences%2C++++++For%3A+Jun+30/26921902.html Thu, 13 Aug 2026 16:32:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+13/26921560.html si-local-file:///var/storage/secattach/20260813/26921560.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+13/26921560.html Thu, 13 Aug 2026 16:20:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+13/26921560.html si-local-file:///var/storage/secattach/20260813/26921560.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+13/26921560.html Thu, 13 Aug 2026 16:20:00 -0400 ENSC O.37556634 http://www.streetinsider.com/Press+Releases/Ensysce+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26921253.html <p><i><strong>Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome</strong></i><br/><i><strong>Up to $77 million in new funding with the acquisition of Cy Biopharma</strong></i><br/><i><strong>Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET</strong></i></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 13, 2026 / </strong>Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.</p><p>On August 6, http://www.streetinsider.com/Press+Releases/Ensysce+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26921253.html Thu, 13 Aug 2026 16:15:00 -0400 ENSC http://www.streetinsider.com/ACCESS+Newswire/Ensysce+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26921253.html <p><i><strong>Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome</strong></i><br/><i><strong>Up to $77 million in new funding with the acquisition of Cy Biopharma</strong></i><br/><i><strong>Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET</strong></i></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 13, 2026 / </strong>Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today reported financial and operational results for the second quarter ended June 30, 2026.</p><p>On August 6, http://www.streetinsider.com/ACCESS+Newswire/Ensysce+Biosciences+Reports+Second+Quarter+2026+Financial+Results+and+Recent+Business+Highlights/26921253.html Thu, 13 Aug 2026 16:15:00 -0400 ENSC http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05++Filed+by%3A+Morrison+James+William/26897767.html si-local-file:///var/storage/secattach/20260810/26897767.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05++Filed+by%3A+Morrison+James+William/26897767.html Mon, 10 Aug 2026 16:06:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05++Filed+by%3A+Morrison+James+William/26897767.html si-local-file:///var/storage/secattach/20260810/26897767.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05++Filed+by%3A+Morrison+James+William/26897767.html Mon, 10 Aug 2026 16:06:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26883137.html si-local-file:///var/storage/secattach/20260806/26883137.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26883137.html Thu, 06 Aug 2026 15:45:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26883137.html si-local-file:///var/storage/secattach/20260806/26883137.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26883137.html Thu, 06 Aug 2026 15:45:00 -0400 ENSC O.37556634 http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Press+Releases/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html <p>DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) --  (<a href="https://www.globenewswire.com/Tracker?data=2GbADOnMjmzSf5VQGjoz7kbTsY9OnpF4dPeV8nA5eJYQ3mbKEyJSv9-CZ-OSfTZ_It-wQI_Mmv-GNHGypvAGbwYToInPjVbYNVGZ1fLaTjo=" rel="nofollow" target="_blank">https://247mnn.com/</a>) – <a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPgv5XUqXDoUzAh9CeeCR4di67fv-VIVWUy7GOKHiciYMYD3t1ed6DBp-dZ97ouMNnwyJRXGH_rEN9ejoXN0n8OE=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (NASDAQ: CLRO)</strong>, <a href="https://www.globenewswire.com/Tracker?data=krJXO7IpdzzVEVfXK6RlvtuRSnL8QgfC4S3ReJoLUjFaEzYW6ZJK9Pwv5qhzDXOLqIMd06Xwjt0JApaoqK4ADoOjIBBQYyhif7OTJISTBSq7LEQdb9KY-SqtsfJRyDUd" rel="nofollow" target="_blank"><strong><u>NeOnc Technologies</u></strong></a><strong> (NASDAQ: NTHI)</strong>, <a href="https://www.globenewswire.com/Tracker?data=HTGtEfPCFtcixTYemLTJ1i4zx2ybZu5wb4H2OmHwbxIY8I_wbJL1QvQhSHeqvoJ-16bR6_ca36jMMyxCfO6bItXNiyi-dnvjQG4B2iiCL4F08x3oVcirV-ZXmZA8xckK" rel="nofollow" target="_blank"><strong>Iovance Biotherapeutics</strong></a><strong> (NASDAQ:IOVA)</strong>, and <a href="https://www.globenewswire.com/Tracker?data=vf1KrJ2dmXGJeQfqTKzXsAA7qYdEd11M4MmhDSHIVi-hNI3Xrh71SdMmtJwooBzF9xbIL6xTcXaMTneJbwEtP4m0jD2D3K3oH4KfM2ZEAAT4JEhiBLXUtbnjNJj6BfSP" rel="nofollow" target="_blank"><strong>Ensysce Biosciences</strong></a><strong> (NASDAQ:ENSC)</strong> are covered in today’s roundup.</p> <p><strong>ClearOne Advances Toward Neurotechnology Transformation</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=xuxUDRZCTy-tT5z-YIYWPiBL0vSYzH9IL68g_JoJdbjNL3YHETgdvlYAQmFJ0jrmj2jycvgrINhlzXWG5MSC61jG7_ZRzIV89zlw_4YCEbc=" rel="nofollow" target="_blank"><strong>ClearOne</strong></a><strong> (</strong><strong>NASDAQ:CLRO</strong><strong>)</strong> continues moving closer to completing its planned transformation into a neurotechnology company as new SEC filings remove several key uncertainties surrounding its pending acquisition of Cortigent, a wholly owned subsidiary of <strong>Vivani Medical (</strong><strong>NASDAQ:VANI</strong><strong>)</strong>, which was first announced on July 2, as investors http://www.streetinsider.com/Globe+Newswire/Why+Investors+Are+Watching+These+Healthcare+Movers/26882092.html Thu, 06 Aug 2026 12:31:07 -0400 CLRO ENSC IOVA NTHI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26879579.html si-local-file:///var/storage/secattach/20260806/26879579.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26879579.html Thu, 06 Aug 2026 08:21:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26879579.html si-local-file:///var/storage/secattach/20260806/26879579.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Aug+05/26879579.html Thu, 06 Aug 2026 08:21:00 -0400 ENSC O.37556634 http://www.streetinsider.com/Mergers+and+Acquisitions/Ensysce+Biosciences+acquires+Cy+Biopharma+with+up+to+%2477M+financing/26879271.html <p>Ensysce Biosciences, Inc. (NASDAQ: ENSC) has completed the acquisition of privately held Cy Biopharma, Inc., a clinical-stage biotechnology company developing neuroplastogenic therapies for complex pain disorders, according to a press release dated August 6, 2026.</p> <p>Concurrent with the acquisition, Ensysce entered into a definitive agreement to sell Series C non-voting convertible preferred stock in a private placement expected to generate approximately $21.5 million in gross proceeds at initial close, before placement agent fees and other expenses. The acquisition also brought in $17.1 million in cash from a pre-acquisition convertible note financing completed by Cy Biopharma. An additional tranche of up to http://www.streetinsider.com/Mergers+and+Acquisitions/Ensysce+Biosciences+acquires+Cy+Biopharma+with+up+to+%2477M+financing/26879271.html Thu, 06 Aug 2026 08:01:15 -0400 ENSC http://www.streetinsider.com/Press+Releases/Ensysce+Biosciences+Announces+Acquisition+of+Cy+Biopharma+and+up+to+%2477+Million+Private+Financing/26879253.html <p><i><strong>Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)</strong></i></p><p><i><strong>Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma's cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestone</strong></i></p><p><i><strong>Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development</strong></i></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong><a rel="nofollow" http://www.streetinsider.com/Press+Releases/Ensysce+Biosciences+Announces+Acquisition+of+Cy+Biopharma+and+up+to+%2477+Million+Private+Financing/26879253.html Thu, 06 Aug 2026 08:00:00 -0400 ENSC http://www.streetinsider.com/ACCESS+Newswire/Ensysce+Biosciences+Announces+Acquisition+of+Cy+Biopharma+and+up+to+%2477+Million+Private+Financing/26879253.html <p><i><strong>Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)</strong></i></p><p><i><strong>Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma's cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestone</strong></i></p><p><i><strong>Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development</strong></i></p> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 6, 2026 / </strong><a rel="nofollow" http://www.streetinsider.com/ACCESS+Newswire/Ensysce+Biosciences+Announces+Acquisition+of+Cy+Biopharma+and+up+to+%2477+Million+Private+Financing/26879253.html Thu, 06 Aug 2026 08:00:00 -0400 ENSC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Jul+15/26774346.html si-local-file:///var/storage/secattach/20260715/26774346.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Jul+15/26774346.html Wed, 15 Jul 2026 16:16:00 -0400 ENSC O.37556634 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Jul+15/26774346.html si-local-file:///var/storage/secattach/20260715/26774346.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Ensysce+Biosciences%2C++++++For%3A+Jul+15/26774346.html Wed, 15 Jul 2026 16:16:00 -0400 ENSC O.37556634